Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder

Body Dysmorphic Disorders Clinical Trial

Official title:

Internet-delivered Cognitive-behaviour Therapy for Adolescents With Body Dysmorphic Disorder: A Feasibility Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05078320
• Other study ID #: 2021-01942
• Status: Completed
• Phase: N/A
• Start date: October 22, 2021
• Est. completion date: June 26, 2023

Study information

• Verified date: October 2023
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to investigate whether a therapist-guided Internet-delivered cognitive behaviour therapy (ICBT) programme is feasible for adolescents with body dysmorphic disorder (BDD). The aim is to evaluate feasibility and provide preliminary efficacy data.

Description:

Rationale for study: BDD is a prevalent and impairing condition that can be effectively treated with cognitive-behaviour therapy (CBT). However, CBT for BDD is a highly specialised treatment and a majority of adolescents do not have access to it. ICBT can be a way to increase the availability of effective psychological treatments. No study to date has evaluated the feasibility of ICBT for adolescent BDD, but the experience in adults with BDD treated with ICBT is encouraging. Objectives: To investigate whether a therapist-guided Internet-delivered cognitive behaviour therapy (ICBT) programme is feasible for adolescents with body dysmorphic disorder (BDD). Specifically, the aim is to:(a) establish participant retention, ease of recruitment, acceptability, credibility, and satisfaction, (b) evaluate potential adverse events, and (c) provide preliminary efficacy data. Trial design and methods: Participants will be recruited nationally and will be offered 12 modules of ICBT for BDD, delivered over a period of 14 weeks. Participants will be assessed before, during, and after treatment, and up to 12 months after the end of the treatment. ICBT non-responders, assessed at post-treatment and one-, two-, and three-months after completing treatment, will be offered CBT delivered via video format (at post-treatment and after the 1MFU and the 2MFU) or traditional face-to-face (F2F) CBT at the OCD and Related Disorders Clinic for Children and Adolescents in Stockholm (after the 3MFU). The primary outcome is feasibility, as measured by examining rates of participant retention, treatment completion and adherence to treatment content, treatment acceptability, treatment credibility, treatment satisfaction and adverse events during the treatment. Secondary outcomes include improvement in clinician-reported BDD symptoms, as well as improvement in other clinical measures assessing disorder severity, disorder improvement, self-reported BDD symptoms, depressive symptoms, and functional impairment. Sample: 20 adolescents and their primary caregivers. Statistical analysis: Retention, acceptability, credibility, and treatment satisfaction. For retention and acceptability, information on ease of recruitment, number of completed modules, and attrition rates will collected and presented in a descriptive manner. Results from a credibility scale will be summarized in group means and standard deviations. Results from a treatment satisfaction scale will be summarized in group means and standard deviation. Potential adverse events: Type and impact of all potential adverse events will be measured with a specific scale and presented descriptively. Preliminary efficacy: Clinical measures of treatment outcomes will be measured via clinician-reported and self- and parent-reported measures and analysed through linear mixed models to detect within group change over time. Within-group effect sizes will be estimated with Cohen's d. Treatment response: The proportion of treatment responders will be calculated. Treatment response will be defined as a ≥30% reduction on the BDD-YBOCS-A, respective to the baseline score. Further, the investigators will also calculate how many participants are on full or partial symptom remission, defined as a score ⩽16 on the BDD-YBOCS-A.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 26, 2023
• Est. primary completion date: September 6, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Age 12 to 17 years, confirmed by the caregiver and subsequently by the patient record system Take Care.

2. A diagnosis of BDD, based on the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), confirmed by the assessor at the pre-treatment assessment.

3. A total BDD severity score on the BDD-YBOCS-A =24. confirmed by the clinician-reported BDD-YBOCS-A performed at the pre-treatment assessment.

4. A minimum of one available caregiver (parent) to support the child/adolescent throughout the treatment. Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.

5. Regular access to a desktop or laptop computer connected to the Internet, with the ability to receive e-mails, as well as a mobile phone to receive SMS (one of each per family is enough). Confirmed by the caregiver at the telephone screening or/and pre-treatment assessment.

Exclusion Criteria:

1. Previous CBT for BDD for a minimum of eight sessions with a qualified therapist within the 12 months prior to assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.

2. Simultaneous psychological treatment for BDD, confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.

3. Initiation, adjustment or change of any selective serotonin reuptake inhibitors (SSRI) within the six weeks prior to the pre-treatment assessment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment.

4. A diagnosis of organic brain disorder, intellectual disability or a psychiatric disorder (such as psychosis, bipolar disorder or eating disorder) that could interfere with the completion of the treatment. Confirmed by the caregiver at the telephone screening and/or pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the MINI-KID interview.

5. Immediate risk to self or others requiring urgent medical attention, such as current risk of suicide or self-injurious behaviours. Confirmed by the assessor at the telephone screening and/or face-to-face or video conference pre-treatment assessment, with help of information from the caregiver and the child/adolescent, and the suicide questions on the MINI-KID interview.

6. Child and caregiver not able to read and communicate in Swedish. Confirmed by the caregiver or assessor at the telephone screening and/or pre-treatment assessment.

Related Conditions & MeSH terms

• Body Dysmorphic Disorders
• Dysmorphophobia

Intervention

Behavioral:
• Exposure and response prevention (ERP)
The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks. The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP). Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns.

Locations

Country	Name	City	State
Sweden	Karolinska Institutet	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Mataix-Cols D, Fernandez de la Cruz L, Isomura K, Anson M, Turner C, Monzani B, Cadman J, Bowyer L, Heyman I, Veale D, Krebs G. A Pilot Randomized Controlled Trial of Cognitive-Behavioral Therapy for Adolescents With Body Dysmorphic Disorder. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):895-904. doi: 10.1016/j.jaac.2015.08.011. Epub 2015 Sep 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Therapist platform time	Therapist platform time is automatically logged in the internet treatment platform. Separate data for children and parents.	Week 14
Other	Therapist telephone time	Therapist telephone time is manually logged in a spreadsheet throughout the trial. Separate data for children and parents.	Week 14
Primary	Treatment credibility questionnaire	Questionnaire developed by the research team. Used to assess treatment credibility. Separate versions for the child/adolescent and the parent are used. Range: 0-12, high scores means better outcome.	Mid-treatment (3 weeks post-baseline)
Primary	Treatment satisfaction questionnaire	Questionnaire developed by the research team. Used to assess treatment satisfaction. Separate versions for the child/adolescent and the parent are used. Range: 0-36, high scores means better outcome.	3-month follow-up.
Primary	internet intervention Patient Adherence Scale (iiPAS) Mid-treatment	Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.	Mid-treatment (6 weeks post-baseline)
Primary	internet intervention Patient Adherence Scale (iiPAS) Post-treatment	Used to assess the child/adolescent's adherence to the internet-delivered treatment. Range: 0-20, high scores means better outcome.	Week 14.
Primary	Negative effects questionnaire - Mid-treatment	Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.	Week 6
Primary	Negative effects questionnaire - Post-treatment	Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.	Week 14
Primary	Negative effects questionnaire - 3 months follow-up	Used to assess side effects/adverse events for the child/adolescent. Parent-reported. Range: 0-100, low scores means better outcome.	3 months follow-up
Primary	Ease of recruitment: Time to recruit	Time to recruit 20 participants.	From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Primary	Ease of recruitment: Amount of participants accepting participation after screening	Amount of participants accepting/declining participation after telephone screening	From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Primary	Ease of recruitment: Amount of participants accepting participation after assessment	Amount of participants accepting/declining participation after initial assessment.	From start of recruitment until 20 participants have been included. Anticipated time frame: 2-3 months
Primary	Number of completed chapters in the internet treatment platform	Number of completed chapters is automatically logged in the internet treatment platform. Separate data for children and parents.	Week 14
Primary	Participant retention	Number of included participants completing treatment.	Week 14.
Secondary	Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, Adolescent version (BDD-YBOCS-A)	Used to assess BDD symptom severity. Clinician-rated, semi-structured interview. Range: 0-48, low scores means better outcome.	Baseline; week 14; 1-, 2-, 3-, 6- and 12-month follow-up.
Secondary	Clinical Global Impression - Severity (CGI-S)	Used to provide an overall rating of the BDD severity. Clinician-rated. Range: 1-7, low scores means better outcome.	Baseline; week 14; 3-, 6- and 12-month follow-up.
Secondary	Clinical Global Impression - Improvement (CGI-I)	Used to assess global improvement. Clinician-rated. Range: 1-7, low scores means better outcome.	Week 14; 3-, 6- and 12-month follow-up.
Secondary	Children's Global Assessment Scale (CGAS)	Used to assess global improvement. Clinician-rated. Range: 1-100, high scores means better outcome.	Baseline; week 14; 3-, 6- and 12-month follow-up.
Secondary	Appearance Anxiety Index (AAI)	A self-reported measure that covers cognitions and behaviours typical of BDD. Range: 0-40, low scores means better outcome.	Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Secondary	Short Mood and Feeling Questionnaire - child version (SMFQ) + additional suicide item	Used to assess depressive symptoms and suicidal ideation. Child/adolescent-reported. Range: 0-29, low scores means better outcome.	Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Secondary	Short Mood and Feeling Questionnaire - parental version (SMFQ) + additional suicide item	Used to assess depressive symptoms and suicidal ideation in the adolescent. Parent-reported. Range: 0-29, low scores means better outcome.	Baseline; week 3, 6, 9, 14; 3-, 6- and 12-month follow-up.
Secondary	The Work and Social Adjustment Scale - Youth Version (WSAS-Y)	A self-reported instrument assessing functional impairment. Range: 0-40, low scores means better outcome.	Baseline; week 6, 14; 3-, 6- and 12-month follow-up.
Secondary	The Work and Social Adjustment Scale - Parent Version (WSAS-P)	A parent-reported instrument assessing functional impairment in the adolescent. Range: 0-40, low scores means better outcome.	Baseline; week 6, 14; 3-, 6- and 12-month follow-up.
Secondary	CRAFFT (acronym for the key words Car, Relax, Alone, Forget, Friends and Trouble)	A short self-reported instrument used to identify substance use and substance use disorder. Range: 0-6, low scores means better outcome.	Baseline; week 14; 3-, 6- and 12-month follow-up.
Secondary	KIDSCREEN-10	Used to assess quality of life. Separate versions for the child/adolescent and the parent are used. Range: 10-50, high scores means better outcome.	Baseline; week 14; 3-, 6- and 12-month follow-up.